Fertility and Sterility
Volume 91, Issue 2 , Pages 456-488, February 2009

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

  • Ricardo Azziz, M.D., M.P.H.

      Affiliations

    • Cedars-Sinai Medical Center and The David Geffen School of Medicine at UCLA, Los Angeles, California (Task Force Chair)
  • ,
  • Enrico Carmina, M.D.

      Affiliations

    • University of Palermo, Palermo, Italy
    • Corresponding Author InformationReprint requests: Enrico Carmina, M.D., Department of Clinical Medicine, University of Palermo, via delle Croci 47, 90139 Palermo, Italy (FAX: +39-091-655-5995).
  • ,
  • Didier Dewailly, M.D.

      Affiliations

    • Lille University Hospital, Lille, France
  • ,
  • Evanthia Diamanti-Kandarakis, M.D.

      Affiliations

    • University of Athens Medical School, Athens, Greece
  • ,
  • Héctor F. Escobar-Morreale, M.D., Ph.D.

      Affiliations

    • Hospital Ramon y Cajal, Madrid, Spain
  • ,
  • Walter Futterweit, M.D.

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
  • ,
  • Onno E. Janssen, M.D.

      Affiliations

    • University of Essen, Essen, Germany
  • ,
  • Richard S. Legro, M.D.

      Affiliations

    • Pennsylvania State University School of Medicine, Hershey, Pennsylvania
  • ,
  • Robert J. Norman, M.D.

      Affiliations

    • University of Adelaide, Adelaide, Australia
  • ,
  • Ann E. Taylor

      Affiliations

    • Novartis, Cambridge, Massachusetts
  • ,
  • Selma F. Witchel, M.D.

      Affiliations

    • Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
  • ,
  • (Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society)

      Affiliations

    • Formerly the Androgen Excess Society.

Received 12 February 2008; received in revised form 19 June 2008; accepted 23 June 2008. published online 23 October 2008.

Objective

To review all available data and recommend a definition for polycystic ovary syndrome (PCOS) based on published peer-reviewed data, whether already in use or not, to guide clinical diagnosis and future research.

Design

Literature review and expert consensus.

Setting

Professional society.

Patients

None.

Intervention(s)

None.

Main Outcome Measure(s)

A systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, to identify studies evaluating the epidemiology or phenotypic aspects of PCOS.

Result(s)

The Task Force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and critiqued by the Androgen Excess and PCOS (AE-PCOS) Society AE-PCOS Board of Directors. No section was finalized until all members were satisfied with the contents, and minority opinions noted. Statements were not included that were not supported by peer-reviewed evidence.

Conclusion(s)

Based on the available data, it is the view of the AE-PCOS Society Task Force that PCOS should be defined by the presence of hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo-anovulation and/or polycystic ovaries), and the exclusion of related disorders. However, a minority considered the possibility that there may be forms of PCOS without overt evidence of hyperandrogenism, but recognized that more data are required before validating this supposition. Finally, the Task Force recognized and fully expects that the definition of this syndrome will evolve over time to incorporate new research findings.

Key Words: Polycystic ovary syndrome, hirsutism, menstrual dysfunction, phenotype, criteria

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 R.A. is a consultant for drug development at Proctor & Gamble. E.C. has nothing to disclose. D.D. has nothing to disclose. E.D.-K. has nothing to declare. H.F.E.-M. has nothing to disclose. W.F. has nothing to disclose. O.E.J. has nothing to disclose. R.S.L. is a consultant for Glaxo Smith Kline, Ferring, Quat. Rx, Organon, Serono, and Solvay. R.J.N. has nothing to disclose. A.E.T. is an employee of Novartis. S.F.W. has nothing to disclose.

PII: S0015-0282(08)01392-7

doi:10.1016/j.fertnstert.2008.06.035

Fertility and Sterility
Volume 91, Issue 2 , Pages 456-488, February 2009